These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12389591)

  • 41. Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(1):31-8. PubMed ID: 12684591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxaliplatin-induced Evan's syndrome.
    Earle CC; Chen WY; Ryan DP; Mayer RJ
    Br J Cancer; 2001 Feb; 84(3):441. PubMed ID: 11161414
    [No Abstract]   [Full Text] [Related]  

  • 43. The emerging role of oxaliplatin in the treatment of gastric cancer.
    Zaniboni A; Meriggi F
    J Chemother; 2005 Dec; 17(6):656-62. PubMed ID: 16433197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
    Quek R; Lim WT; Foo KF; Koo WH; A-Manaf A; Toh HC
    Acta Oncol; 2007; 46(7):1032-4. PubMed ID: 17917832
    [No Abstract]   [Full Text] [Related]  

  • 45. In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines.
    van Iersel LB; Koudijs TM; Hoekman EJ; Janssen-van Rhijn CM; Vahrmeijer AL; Nortier JW; van de Velde CJ; Gelderblom H; Kuppen PJ
    J Surg Res; 2011 May; 167(2):273-8. PubMed ID: 20036390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
    Ducreux M; Louvet C; Bekradda M; Cvitkovic E
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):47-53. PubMed ID: 9609108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P190
    Wang H; Wang ZY; Xin CH; Shang YH; Jing R; Yan FH; Feng SZ
    Chin Med J (Engl); 2017 Feb; 130(4):495-496. PubMed ID: 28218227
    [No Abstract]   [Full Text] [Related]  

  • 48. [Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects].
    Dominici C; Petrucci F; Alimonti A; La Torre F; Cifani A; Caroli S
    Ann Ist Super Sanita; 1995; 31(2):289-94. PubMed ID: 8561393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Current status and prospects of the clinical chemotherapy of tumorous diseases].
    Perevodchikova NI
    Vestn Akad Med Nauk SSSR; 1986; (5):3-8. PubMed ID: 2425507
    [No Abstract]   [Full Text] [Related]  

  • 50. Severe anaphylactic reaction to oxaliplatin.
    Alliot C; Messouak D; Beets C; Rapin JP
    Clin Oncol (R Coll Radiol); 2001; 13(3):236. PubMed ID: 11527302
    [No Abstract]   [Full Text] [Related]  

  • 51. [Treatment of patients with intestinal cancer. Increased neurotoxicity after oxaliplatin and related liver metastasis].
    Junker A; Kretzschmar A; Böhm U; Tannapfel A; Langenbahn D; Pieck AC; Jaehde U
    Med Monatsschr Pharm; 2004 Oct; 27(10):349-52. PubMed ID: 15527179
    [No Abstract]   [Full Text] [Related]  

  • 52. Second-line therapy in colorectal cancer.
    Berlin J
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
    Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
    Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
    Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line.
    Kjellström J; Kjellén E; Johnsson A
    Acta Oncol; 2005; 44(7):687-93. PubMed ID: 16227158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cisplatin and related anticancer drugs: recent advances and insights.
    Barnes KR; Lippard SJ
    Met Ions Biol Syst; 2004; 42():143-77. PubMed ID: 15206102
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.
    Spunt SL; Freeman BB; Billups CA; McPherson V; Khan RB; Pratt CB; Stewart CF
    J Clin Oncol; 2007 Jun; 25(16):2274-80. PubMed ID: 17538173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral cytotoxic drugs.
    Gridelli C; Rossi A; Guerriero C; Nicolella D; Ferrara C; Del Gaizo F; Colantuoni G; Airoma G; Maione P
    Suppl Tumori; 2002; 1(4):S19-23. PubMed ID: 12415809
    [No Abstract]   [Full Text] [Related]  

  • 59. Oxaliplatin in the treatment of colorectal cancer.
    Kim GP; Erlichman C
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Results of a phase-I clinical study of carboplatin--(cyclobutane-1,1-dicarboxylate)diamineplatinum (II)].
    Gorbunova VA
    Vestn Akad Med Nauk SSSR; 1986; (5):45-7. PubMed ID: 3524054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.